Immunome Inc. (IMNM) stock soared 5.43% during intraday trading on Wednesday, driven by a series of positive analyst actions and price target increases.
The rally followed several bullish research notes from major financial institutions. JPMorgan raised its price target on Immunome to $39 from $35 while maintaining an Overweight rating. Similarly, Craig-Hallum increased its target to $36 from $33 and reiterated a Buy rating on the shares. Stephens & Co. maintained its Overweight rating on the stock, while Piper Sandler continued to recommend the stock with a Buy rating and a $33 price target.
These analyst actions collectively contributed to positive investor sentiment, leading to the significant price appreciation during the trading session.